All Drug Discovery articles – Page 6
-
NewsNew method boosts production of non-natural amino acids for peptide assembly
A team of researchers has developed a faster, simpler method for creating non-natural amino acids and assemble them into peptides, a breakthrough that could accelerate peptide research and provide new tools for designing drugs.
-
NewsLario raises $2.4m for neurological drug development
Lario Therapeutics has secured $2.4 million in funding from The Michael J. Fox Foundation for Parkinson’s Research and Wellcome to accelerate development of its neuronal calcium channel platform.
-
NewsTargeting senescent cells may reduce postpartum breast cancer risk
A study from the Institut Pasteur reveals how cellular senescence during mammary gland involution after pregnancy may both aid tissue repair and promote postpartum breast cancer.
-
News$3.2m project targets aggressive MDM2 in breast cancer
A University of Houston scientist has joined a $3.2 million research collaboration to develop a new drug targeting one of the key drivers of triple-negative breast cancer.
-
NewsInsilico and MSK partner on AI research for gastroesophageal cancer
A new research collaboration between Insilico Medicine and Memorial Sloan Kettering Cancer Center aims to harness generative AI technology to identify novel therapeutic targets for gastroesophageal cancers.
-
ArticleEngineering the next generation of T-cell engagers
T-cell engagers are a branch of immunotherapy that has undergone considerable change since their clinical inception. Andrew J Souers, VP, Oncology Discovery Research at AbbVie, elucidates the current understanding of their biology and expanding focus areas of application.
-
NewsMemory-linked brain cells offer new obesity target for future therapies
Scientists have identified a brain circuit that connects contextual memory with appetite, advancing understanding of binge eating and obesity while highlighting a promising new target for drug discovery.
-
NewsNew SerpinB2 immune cell discovery could reverse type 2 diabetes
Researchers at the University of Pittsburgh School of Medicine have developed a new approach for tackling insulin resistance and type 2 diabetes by protecting beneficial immune cells in fat tissue.
-
ArticleAI begins to enter Alzheimer’s drug discovery pipelines
Artificial intelligence is increasingly used to analyse large, multimodal Alzheimer’s datasets and inform target discovery and trial design. A new JPAD special issue highlights how these methods are moving from experimentation towards practical application in drug discovery.
-
NewsLaunaea herb could provide new treatments for peptic ulcers
A herb called Launaea nudicaulis could be used to treat peptic ulcers, with early research suggesting both gastroprotective benefits and potential applications in natural product drug discovery.
-
NewsHDAC11 protein identified as potential target for Duchenne muscular dystrophy
A new preclinical study has shown that reducing the protein HDAC11 could slow muscle degeneration in Duchenne muscular dystrophy, providing a potential target for future therapies.
-
NewsCC023 mice reveal how ALS can develop after viral infections
Researchers have discovered a mouse strain that mirrors ALS in humans following a viral infection, offering new insights into how the disease develops, potentially opening new pathways for early diagnosis and drug development.
-
NewsBrain discovery could improve drugs targeting amyloid diseases
New research shows the brain can intentionally form amyloids to store memories, challenging decades of thinking about neurodegenerative disease and pointing towards new strategies for drug discovery.
-
NewsTargeting cPLA2 enzyme may reduce brain inflammation in Alzheimer’s
Researchers have identified new drug candidates that selectively target the cPLA2 enzyme, a key driver of brain inflammation linked to Alzheimer’s disease, offering a potential new approach to reducing risk in people with the APOE4 gene.
-
ArticleDrug development in 2026: NAMs, safety and regulatory changes
2026 is set to be a pivotal year for drug discovery, with advances in NAMs and evolving regulatory approaches promising faster, safer early drug development and accelerated delivery of therapies for patients with rare or unmet medical needs.
-
NewsELRIG announces keynote speakers for Cell and Gene Therapy 2026 in Cambridge
ELRIG (European Laboratory Research & Innovation Group) has announced the keynote speakers for its inaugural Cell and Gene Therapy 2026 conference, taking place at Hinxton Hall in Cambridge from 9–10 March.
-
NewsNew generative AI method could make drug discovery faster
A newly developed AI-driven technique could dramatically speed up the discovery of drugs and advanced materials, enabling scientists to design chemically valid, property-targeted molecules in minutes rather than years.
-
NewsHIV drug Maraviroc could be used to slow glioblastoma growth
Researchers have discovered how seemingly supportive brain cells help glioblastoma thrive, whilst identifying an existing HIV drug, Maraviroc, that could be repurposed to slow tumour growth.
-
ArticleTargeting inflammatory cell death to tackle relapse in AML
Relapse in acute myeloid leukaemia is driven by malignant cells that resist standard treatment. A synthetic cytokine approach in development targets inflammatory cell death pathways to suppress leukaemic cells while preserving healthy haematopoiesis.
-
NewsNew Alco5 platform could advance cancer antibody therapies
Biotech company, Tubulis, has published preclinical data on its Alco5 antibody-drug conjugate platform, demonstrating the ability to link antibodies with previously inaccessible hydroxy-containing drugs.